Bioventix (LON:BVXP) Sets New 1-Year Low – Time to Sell?

Shares of Bioventix PLC (LON:BVXP) hit a new 52-week low on Thursday . The stock traded as low as GBX 1,666 and last traded at GBX 1,725, with a volume of 20017 shares traded. The stock had previously closed at GBX 1,765.

Bioventix Stock Performance

The company has a fifty day simple moving average of GBX 2,115.61 and a two-hundred day simple moving average of GBX 2,434.21. The firm has a market capitalization of £87.31 million, a PE ratio of 11.66 and a beta of 0.35.

Bioventix (LON:BVXP) last released its quarterly earnings data on Monday, October 27th. The biotechnology company reported GBX 145.27 earnings per share for the quarter. Bioventix had a return on equity of 69.09% and a net margin of 59.51%. On average, equities analysts anticipate that Bioventix PLC will post 166.3066955 earnings per share for the current fiscal year.

Insider Transactions at Bioventix

In other Bioventix news, insider Ian James Nicholson acquired 500 shares of the company’s stock in a transaction dated Wednesday, October 29th. The shares were purchased at an average cost of GBX 1,865 per share, for a total transaction of £9,325. Also, insider Bruce Hiscock acquired 150 shares of the business’s stock in a transaction that occurred on Tuesday, November 25th. The shares were acquired at an average cost of GBX 2,071 per share, for a total transaction of £3,106.50. In the last quarter, insiders acquired 1,644 shares of company stock valued at $3,424,721. Company insiders own 6.16% of the company’s stock.

About Bioventix

Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. The company offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, oncology, and miscellaneous indications; and Pyrene (HOP-G) ELISA kit to monitor human exposure to industrial pollutants.